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PROBLEMS IN THE DESIGNING OF ANTIMETABOLITESt
Historically, the most useful medicinal agents have been obtained by
empirical screening or by the chemical modification of compounds of known
activity in the hope of making them more effective. To these approaches
a new one was added in recent years-antimetabolites.
An antimetabolite may be defined as a compound bearing structural
resemblance to a metabolite and capable of being attached to the enzyme
for which the metabolite serves as the normal substrate. The enzyme-
antimetabolite complex, however, is incapable of undergoing the reactions
of the enzyme-metabolite complex and, by interfering with the modification
of the metabolite, a specific biochemical lesion is created.
The best example of truly effective antimetabolites is the sulfonamides,
still among our most useful antibacterial agents. Sulfonamides are anti-
metabolites of p-aminobenzoic acid, which in turn is used by susceptible
bacteria for the synthesis of coenzymes structurally related to pteroyl-
glutamic (folic) acid.' The animal host cannot synthesize its own folic acid;
most bacteria, on the other hand, cannot utilize preformed folic acid. Here,
a clean-cut, qualitative metabolic difference between invading cells and the
cells of the host has been exploited with considerable success.
After the discovery of the mode of action of the sulfa drugs which,
incidentally, were found through screening synthetic dyes, rather than by
the application of the principles discussed above, it seemed likely that the
exploitation of biochemical differences between host and invading cells
(whether bacteria, viruses, or neoplasms) would lead to the synthesis of
a large number of potent drugs.
This approach, the design of antimetabolites, did lead to the synthesis of
large numbers oforganic compounds. However, while thousands of potential
antimetabolites have been synthesized, the number of useful drugs among
them has been disappointingly small. Certainly the most important medi-
cinal agents to be introduced during the last twenty years, the antibiotics,
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did not originate in chemical laboratories but in such unlikely places as,
for instance, the wounded knee of a little girl, a rotten cantaloupe, or in
some of almost innumerable samples of soil. These antibiotic compounds,
which have revolutionized the treatment of bacterial diseases, are the fruit of
purely empirical screening, even though their therapeutic usefulness has
in some cases been improved by chemical modification.
One of the reasons for the failure of so many antimetabolites may lie in
the necessarily mechanical way in which they are being designed. Thus,
as soon as the structure of a new metabolite is established, even when its
biochemical role may not have been elucidated, dozens of potential "anti-
metabolites" are described in the literature within a matter of months.
Generally, these are designed by the application of rather simple rules,
for instance:
1. Only one substituent group should be changed at one time; multiple
alterations in the structure of a metabolite are to be avoided. This rule
is followed fairly generally, even though Amethopterin ("Metho-
trexate"), one of the most useful antileukemic agents now available,
is a doubly modified analog of folic acid."
2. Hydroxy (-OH) groups may be interchanged with amino (-NH2)
groups. Examples: aminopterin8'; 2,6-diaminopurine.'
3. Oxygen may be interchanged with sulfur or selenium. Examples:
6-mercaptopurine,' 6-selenopurine."'
4. Carboxyl (-COOH) groups may be interchanged with sulfonamide
(-SO2NH2) or methylsulfonyl (-SO2CH3) groups. Examples: the
sulfonamides, uracil-6-methylsulfone.'
5. Methyl (-CH3) groups may be replaced by bromine or iodine.
Examples: 5-bromouracil,'8 5-iododeoxyuridine.'
6. Hydrogen may be replaced by fluorine. Examples: fluroacetate,o
fluorocitrate,'8 5-fluorouracil.8
7. In heterocyclic compounds, carbon and nitrogen may be exchanged in
the ring. Example: 8-azaguanine,' pyrazolo-[3,4-d] pyrimidines,t
6-azauridine.'9
8. Alkylating groups (for instance the -CHN2 or the -N(CH2CH2Cl)2
group) may be introduced. Example: azaserine,' 5-bis(,8-chloroethyl)
aminouracil.'
Unfortunately, for antimetabolites to be effective one needs not only a list
of the metabolite's replaceable groups, but also some information about the
functions of these groups and concerning the nature of the receptor sites to
which they are to be attached. Otherwise, the chemotherapist is in the
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position of a man who, on being asked to jam a lock by altering a key
looking like this,
changes it to look like this:
since he did not know which end of the key was functional. This analogy
also suggests that metabolites and antimetabolites do not-as stated by
Woolley-have to resemble each other as much as possible, but that their
structure has to be similar primarily in that part of the molecule which fits
an enzyme surface. Thus, decamethonium (I) and atropine (II), which
certainly show
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little structural resemblance to acetylcholine (III), can attach themselves to
some of its receptor sites. Decamethonium can mimic the effects of
acetylcholine at the neuromuscular junctions';
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atropine is a competitive antagonist of acetylcholine at post-ganglionic
parasympathetic endings.'0 It can be seen that through the use of such
considerations the term antimetabolite could be extended to include a large
number of existing medicinal agents.
Unfortunately, information about substrate-enzyme interaction in terms of
chemical mechanisms is very scarce and in most cases antimetabolites have
to be designed without knowing which groups of the metabolite are func-
tional. Even when a group known to be essential can be replaced by another,
there can be no certainty that the change made will not be too great, in which
case structural specificity is lost, or too small, in which case the analog may
even be as functional as the compound which it mimics.
An example ofa change of the latter type can be seen in selenopantethine,'
the selenium analog of the sulfur compound, pantethine, which is the major
component of coenzyme A(IV). The metabolic functions of this coenzyme
are exerted through the formation of S-acyl intermediates,"' so that the
chemical reactions of the whole complex molecule can be referred to its
single atom
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of sulfur. Yet, when this sulfur was replaced by selenium, it was found that
a microorganism requiring preformed pantethine grew just as well, on a
mole for mole basis, on its selenium analog. Although it remains to be
established that the organism, grown on the seleno-compound, contains a
biologically functional seleno-coenzyme A, the probability of this is great.
Another difficulty in working with antimetabolites relates to the assump-
tion that drug and metabolite will behave differently only at the receptor site
where inhibition is to take place, at which point antagonism will occur. At
the same time, the tacit assumption is made that everywhere else in the body,
in terms of metabolism, ability to be carried to the site of action, and toxicity
unrelated to the site of action, metabolite and antimetabolite will behave in
an identical fashion. This assumption, as would be expected, is hardly ever
valid, since the replacement of chemical groups on a substrate by other
groups usually alters the dissociation constant, lipid solubility, chemical
reactivity, and paths of metabolic alteration of the molecule.
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Changes in acid dissociation constant are particularly important, since
the degree to which a drug is dissociated at physiological pH determines
to what extent attachment to, or passage past, charged groups in biological
tissues may occur. Since degree of dissociation stands in an inverse relation-
ship to lipid solubility, it can be seen that as the pKa of a compound is
altered, its ability to reach its site of action will be altered too.1 This is
important, since anything that can be done to enable a functionally effective
antimetabolite to reach its site on the biophase more efficiently than the
metabolite will almost certainly make it a better antagonist.
Lipid solubility, as well as the degree of dissociation, is also important in
enabling drugs to cross the blood-brain barrier."7 Failure to cross this
"barrier" may increase the probability of resistant cells emerging within
the brain' andgreatly diminishes the value of drugs used in the treatment of
diseases in which the central nervous system may be invaded by micro-
organisms or malignant cells.
If the fat solubility of a drug is too low, there are several methods by
means of which it may be increased. The most widely used procedure is the
introduction of long alkyl chains. This usually has the desired effect;
however, the introduction of bulky groups changes the ability of drugs to
attach themselves to receptor sites and may alter their mechanism of action
completely. In a recent example of this it was found that pyridine-2-
aldoxime methiodideTM (V), a reversing agent for acetylcholine esterase
profoundly inhibited by "nerve gases," could not exert its effects in brain
tissue, since the fat solubility of the aldoxime was too low. When its
structure was modified in such a way that the methyl group of the aldoxime-
derivative was replaced by the long-chain, lipid-solubilizing dodecyl group
(VI), the new
-,CH=NQH
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V.
QI..CH=NOH
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compound was very much more lipid soluble and able to affect structures
uninfluenced by the parent compound. However, the introduction of the
long alkyl chain gave the new compound depolarizing properties (which in
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view of its similarity to decamethonium (I) is not too surprising) and
increased its toxicity.2t
Lipid solubility may also be increased by masking ionic groups, for
instance by esterifying carboxyl or alkylating amino or hydroxy groups.
However, since attachment to receptors is usually carried out by the groups
now being altered, this procedure may result in loss of the desired activity.
It can be seen that in altering the fat solubility of a compound it is
desirable to change its size, shape, and dissociation constants as little as
possible. In some cases, this can be accomplished by replacement of oxygen
by sulfur or even by selenium. In a recent study of several series of
homologous heterocyclic oxygen, sulfur, and selenium compounds, it was
found that this method of solubilization, which changes the configuration
of the molecule very little, seems to be a generally effective one.'
The most important difficulty in designing antimetabolites, however, is
not a chemical but a biochemical one. This is the frequent lack of qualitative
metabolic differences between the cells of the host and the cells to be
destroyed. This problem is particularly crucial in the field of cancer chemo-
therapy. Until now no enzymes have been found in malignant cells that are
not present in normal cells.' While it has been reported recently that
neoplasms may be profoundly deficient in some enzymes present in the
host,' this finding would seem to be more useful for designing anti-
metabolites for freeing the tumor from the host than for doing the opposite!
At best, it can be hoped that lack of catabolic enzymes may reduce
preferentially the inactivation of a drug by tumor tissue.
Because of this lack of qualitative biochemical differences between normal
and neoplastic cells, most carcinostatic antimetabolites are toxic to the cells
of the host as well as to the cells of the tumors. Differential toxicity
apparently is determined primarily by the greater rate at which the
metabolite is depleted in the rapidly proliferating cells of the tumor as
compared to the more slowly growing cells of the patient. This means that
the therapeutic indices of these drugs tend to be quite low. When even a
slight degree of drug resistance emerges, the dosage often cannot be raised
enough to overcome it without causing intolerable toxicity to the host.
Since in designing antimetabolites it is important to decide just what one
expects these compounds to do, it is convenient to subdivide them into
several classes. These are:
1. Reversible antimetabolites. Here metabolite and antimetabolite com-
pete for the same receptor sites. Since the inhibitor is bound comparatively
loosely, it may be dislodged as the concentration of the metabolite is
increased. The ratio of the two compounds at which inhibition takes place
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is a function of the relative firmness with which molecules of drug and
molecules of normal substrate are held by the receptor once equilibrium has
been established. If the concentration of both compounds is altered to the
same extent, the degree of inhibition remains the same. The sulfonamides
are representatives of the few effective drugs in this class.
2. Irreversible antimetabolites. Compounds which are bound so firmly
that the metabolite cannot dislodge them at any concentration, may be
subdivided into two groups:
a. Endotoxic antintetabolites. These compounds are similar to the reversi-
ble antimetabolites discussed above in that those groups of the metabolite
are modified through which attachment to the receptor takes place; however,
with endotoxic antimetabolites very firm binding will result. For example,
it has recently been shown that aminopterin and amethopterin are bound
much more firmly to folic acid reductase than is the normal substrate, folic
acid.' Presumably the amino group of the inhibitor is held more strongly
by an acidic site than the analogous hydroxy group of the metabolite.2 It
would seem likely that some essentially irreversible inhibitors of this type
might become reversible as the pH of the system is changed.
b. Toxophoric antimetabolites. This name is proposed for antimetabolites
carrying a highly reactive group (bis(B-chloroethyl)amino-, or diazomethyl
groups, for instance) unrelated in structure and reactivity to any group of
the normal metabolite. Since such substituents are rather bulky as well as
reactive, it would seem desirable that they should not replace any groups
responsible for attachment of the metabolite to the enzyme. Such replace-
ment would be expected to result in loss of specificity of action. Rather, the
toxic group should be adjacent to that area of the substrate at which
attachment occurs, so that once enzyme-antimetabolite interaction has taken
place, nearby sites of the enzyme could be attacked irreversibly with the
formation of a covalent bond. Amino acid-mustards would be expected to
exert their activity in this fashion.
Similarly, it might be hoped that compounds like 5-bis(,83-chloroethyl)
aminouracil' (VII) or 8-bis(A-chloroethyl)amino-purines' (VIII) (or
possibly their ribonucleosides or deoxyribonucleosides) might be incorpo-
rated into nucleic acids and then, through their "mustard" groups, perhaps
cause cross-linking between adjoining Watson-Crick double helices.
° ,CH2CH CC R
1 SCH2 CI CH2CH2 Ca
H H
VII. VIII.
The main problem with antimetabolites of this type would be expected to
lie in the likelihood that they might undergo chemical reaction before having
had time to reach the desired destination.
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For a related discussion of irreversible antimetabolites the reader is
referred to a recent paper by Baker.!
3. Aggregate antimetabolites. This type of compound was first postulated
by Woolley, who suggested that two metabolites known to participate in a
connected metabolic sequence could be converted into an antimetabolite by
being united into a single molecule and proposed the above name.' Actually,
it would seem unnecessary for two different metabolites to be united,
but that it might suffice if two molecules of the same metabolite, or
the same antimetabolite, were connected back to back, that is, linked in
such a way that the chain between them would not interfere with attachment
to receptor sites. Once an antimetabolite of this type would be attached,
the probability of molecules of the metabolite dislodging it at both ends
simultaneously would be rather low. If one end only were displaced, the
probability of re-attachment of this end would be comparable to the proba-
bility of detachment of the other one. Succinoylcholine (IX), a dimer of
acetylcholine, is one of the few examples of this type of compound; it is
a widely used and very effective, neuromuscular blocking agent.' Recently
some 8,8'-bispurinyl alkanes (X) have been synthesized' in the hope that
such compounds might cause cross-linking between adjoining double helices
of DNA and thus interfere with cell replication.
CH1 0 0 CH1
IIt N I.+
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It would now seem to be in order to review whether the antimetabolic
approach has been or is likely to become a successful one. Although it seems
likely that a research program based on the design of antimetabolites, in
the long run will not produce more useful drugs than a program based on a
more empirical basis, much is neglected by such a generalization. Certainly
the likelihood of discovering valuable medicinal agents is particularly remote
for workers synthesizing antimetabolites of compounds the functions of
which are understood quite imperfectly or for workers dealing with anti-
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metabolites of compounds required by the host as much as by the invading
cells.
However, the antimetabolite approach does have some very important
advantages. While a weakly active, empirically designed compound has
little or no scientific value, a weakly active, logically conceived antimetabolite
may be a very valuable tool in gathering information about the metabolic
functions of the compound with which it competes and about the receptor
sites to which it is attached.
Thus, many antimetabolites do not simply compete with the compounds
which they would be expected to mimic. For example, 5-fluorouracil turned
out not to be a uracil antagonist in the body, but was reported as exerting
its antileukemic activity by being converted to the deoxyribonucleotide and
then interfering with the synthesis of thymidylic acid.8 Similarly, 6-azauracil
is converted to the ribonucleotide and interferes with orotidylic acid decar-
boxylase,'2 while 6-mercaptopurine has also been reported to exert its
carcinostatic action at the ribonucleotide level.' It can be seen that such
compounds are very valuable in elucidating the metabolic paths of the
substrates of which they are modifications.
Furthermore, as a biochemical reaction is blocked we may see an
accumulation of the product of the preceding metabolic step; this ulti-
mately may lead to a nullification of the metabolic block. For instance, if in
slow fast
the reaction sequence: A -) B -- C the step B ->C is blocked, we may
be able to isolate the intermediate B, which otherwise might have remained
undiscovered; thus, azaserine has been very helpful in elucidating some
aspects of the biosynthesis of purines.'7
It would also seem that if the structures of metabolites are changed in
such a fashion that their size remains essentially unaltered, but that the
electron density of only one of the reactive groups is modified, much
information about the reaction mechanisms of metabolite-enzyme interaction
could be collected, at least if an isolated enzyme system were used. For
example, a comparative study of the kinetics of ribonucleosidation of purines
(XI) and triazolopyrimidines (XII), would be very interesting. Here, a
R R
H H
ribonucleosidation ribonucleosidation
XI. XII.
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carbon is replaced by an essentially isosteric nitrogen in a position adjacent
to the nitrogen where ribonucleosidation is to occur, altering the electron
density of the latter in a predictable fashion. Since electron density deter-
mines the ease with which electrophilic or nucleophilic reactions may
proceed, the relative rate of ribonucleosidation of isologues of this type
should give us much useful information about the mechanisms involved.
By measuring the dissociation constants of enzyme-substrate complexes
of the enzyme with analogs in which the electrophilic character of only one
group has been altered, we can gain knowledge about the acidity or basicity
of the groups on the enzyme with which binding occurs. This would be
particularly true if such measurements were carried out over a wide pH
range. If, on the other hand, the electron density of the reactive groups is
left unaltered, but the size of the molecule or the distance between the
groups is modified, information can be collected about the shape of the sites
where attachment is to occur. Such an approach has been used very success-
fully by Nachmansohn, Wilson, and their associates, in studying the
receptor sites of acetylcholine esterase with the result that it became possible
to design, on a rational basis, compounds for reversing inhibition of this
enzyme.'
It would seem that at our present state of knowledge, in which we can
discuss enzyme reactions mainly in terms of what substrate is attacked rather
than in terms of the reaction mechanism of the attack, antimetabolites have
their greatest value in explaining the mode of action of metabolites and in
collecting information about receptor sites. The chance of finding useful
drugs, at present, may be no higher than if any other chemotherapeutic
approach were used, but it is intellectually a great deal more satisfying and
much more productive of fundamental information upon which to build
future advances.
Once enzymic reaction mechanisms and receptor sites would be under-
stood in molecular terms rather than in terms of vague generalities, rational
chemotherapy might become a reality. Antimetabolites would seem to be
our most valuable tool for reaching this point.
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